| Title |
Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, February 2012
|
| DOI | 10.2147/tcrm.s23875 |
| Pubmed ID | |
| Authors |
Mao Hagihara, Takumi Umemura, Takeshi Mori, Hiroshige Mikamo |
| Abstract |
Daptomycin is a lipoglycopeptide antibacterial drug that is rapidly bactericidal for methicillin-resistant Staphylococcus aureus (MRSA) infection and has antibiotic activity against a wide range of Gram-positive organisms. It has been approved by the Ministry of Health, Labor and Welfare in Japan for the treatment for bacteremia, right-sided endocarditis, and skin and skin-structure infections, such as necrotizing fasciitis, due to MRSA on the basis of a Phase III trial conducted in Japan since July, 2011. In Japanese Phase I and III trials, daptomycin therapy given at 4 mg/kg and 6 mg/kg once per day was well tolerated and effective as standard therapy for the treatment of acute bacterial skin and skin-structure infections and bacteremia caused by MRSA, but side effects remain to be evaluated in large-scale trials. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 21% |
| Student > Master | 3 | 21% |
| Researcher | 2 | 14% |
| Student > Bachelor | 1 | 7% |
| Librarian | 1 | 7% |
| Other | 2 | 14% |
| Unknown | 2 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 43% |
| Biochemistry, Genetics and Molecular Biology | 1 | 7% |
| Agricultural and Biological Sciences | 1 | 7% |
| Nursing and Health Professions | 1 | 7% |
| Immunology and Microbiology | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 3 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2012.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from Therapeutics and Clinical Risk Management
#1,050
of 1,308 outputs
Outputs of similar age
#206,034
of 254,308 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#6
of 7 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 254,308 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one.